N-Aryl-N′-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure–activity relationship analysis
摘要:
A series of chroman derivatives previously reported as potassium channel openers, as well as some newly synthesized simplified structures, were examined for their in vitro effects on the growth of three human high-grade glioma cell lines: U373, T98G, and Hs683. Significant in vitro growth inhibitory activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the corresponding phenylthioureas. No significant differences were observed in terms of chroman-derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli (Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli (U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow cytometry analyses confirmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase. Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects, while 3e displayed cytotoxic ones. As a result, this work identified phenylurea-type 2,2-dimethylchromans as a new class of antitumor agents to be further explored for an innovative therapeutic approach for high-grade glioma and/or for a possible new mechanism of action. (C) 2012 Elsevier Masson SAS. All rights reserved.
[EN] AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYL EN TANT QU'INHIBITEURS DU FACTEUR D DU COMPLÉMENT ET LEURS UTILISATIONS
申请人:NOVARTIS AG
公开号:WO2015009977A1
公开(公告)日:2015-01-22
The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Syntheses of 4-Aryl Chromanes: A Rearrangement Approach
作者:Pailla Umareddy、Arava Veera Reddy、L. K. Ravindranath
DOI:10.1080/00397911.2015.1015140
日期:2015.5.19
Abstract 4-Aryl chromanes are synthesized from 4-Aryloxy chromanes via a rearrangement methodology. GRAPHICAL ABSTRACT
摘要 4-芳基色满由4-芳氧基色满通过重排方法合成。图形概要
[EN] INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF<br/>[FR] INHIBITEURS DE FACTEURS DU COMPLÉMENT ET LEURS UTILISATIONS
申请人:ANNEXON INC
公开号:WO2022020244A1
公开(公告)日:2022-01-27
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
Production of enantiopure chiral aryl heteroaryl carbinols using whole‐cell <i>Lactobacillus paracasei</i> biotransformation
作者:Engin Şahin
DOI:10.1080/00397911.2019.1707226
日期:2020.2.16
the first example for an enantiopure production of (S)-6-chlorochroman-4-ol (3a), which has many antioxidant activity, by a biological method. For asymmetric bioreduction of other prochiral ketones, these results open way to use of L. paracasei BD87E6 as biocatalysts. Also, the present process shows a hopeful and alternative greensynthesis for the production of enantiopure carbinols in a mild, inexpensive
Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
申请人:BELANGER David B.
公开号:US20160145247A1
公开(公告)日:2016-05-26
The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.